The Immunogenicity of a Single Dose of Hepatitis A Virus Vaccines (Havrix(R) and Epaxal(R)) in Korean Young Adults.
10.3349/ymj.2014.55.1.126
- Author:
Jiseun LIM
1
;
Yeong Jun SONG
;
Woong Sub PARK
;
Haesook SOHN
;
Moo Sik LEE
;
Dong Hoon SHIN
;
Chun Bae KIM
;
Hwasung KIM
;
Gyung Jae OH
;
Moran KI
Author Information
1. Department of Preventive Medicine, Eulji University School of Medicine, Daejeon, Korea. moranki@naver.com
- Publication Type:Original Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
- Keywords:
Hepatitis A virus;
hepatitis A vaccine;
immune;
vaccine;
young adults
- MeSH:
Adolescent;
Adult;
Female;
Hepatitis A/*immunology/*prevention & control;
Hepatitis A Vaccines;
Hepatitis A Virus, Human/*immunology/*pathogenicity;
Humans;
Male;
Young Adult
- From:Yonsei Medical Journal
2014;55(1):126-131
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Assessing the immunogenicity of a single dose of hepatitis A virus (HAV) vaccines is important because some people receive only a single dose. However, previous studies have shown variable results and have not examined the effects of demographic characteristics other than gender. This study was performed to examine the immunogenicity of a single dose of HAV vaccine according to the vaccine type and demographic characteristics in young adults. MATERIALS AND METHODS: Seronegative medical school students were randomly allocated to receive either Havrix or Epaxal. RESULTS: After approximately 11 months, the seroconversion rate in 451 participants was 80.7%. In men, the Havrix group showed a significantly higher seroconversion rate (81.9%) than the Epaxal group (69.2%), whereas both vaccine groups showed similarly high immunogenicity in women (Havrix: 90.1%, Epaxal: 92.9%; P for interaction=0.062). According to the results of a multivariate analysis, Epaxal showed significantly lower immunogenicity than Havrix only in men. Age, obesity, drinking, smoking, and follow-up time did not significantly affect seroconversion in either gender. CONCLUSION: The seroconversion rate of single-dose HAV vaccines was low in men, particularly in those who received Epaxal. Our results suggest that gender effects should be considered when comparing the immunogenicity of different HAV vaccines.
